Biovail Targets Paddock Over Aplenzin ANDA

Law360, New York (March 10, 2010, 5:17 PM EST) -- Biovail Laboratories International SRL has shot off a patent infringement suit against Paddock Laboratories Inc. over its plans to market a generic version of the antidepressant Aplenzin.

Biovail filed the complaint Tuesday in the U.S. District Court for the District of Minnesota, seeking to block the generic-drug maker from bringing its own version of Aplenzin to the market before Biovail's patents expire.

Paddock recently submitted an abbreviated new drug application to the U.S. Food and Drug Administration for approval to sell bupropion hydrobromide extended-release tablets, the...
To view the full article, register now.